



Supplementary Figure S1



Supplementary Figure S1. The lower-dose of TNF-α does not impair ADSC-E viability


A. After treating ADSC-E with 20 ng/ml TNF-α for 24 hours, cell viability was evaluated by WST-1 assay. B. After treating ADSC-E with 20 ng/ml TNF-α for 48 hours, cell viability was evaluated by WST-1 assay. *p* values of less than 0.05 were considered statistically significant (**p* < 0.05, ***p* < 0.01). The data are expressed as the mean ± standard deviation (SD) of three independent experiments.

Supplementary Figure S2



Supplementary Figure S2. The effects of one-time SP treatment on ADSC-E morphology changes under inflammatory conditions.
ADSC-E was treated with SP and 24 later, exposed to TNF- α . The cellular morphology of ADSCs was observed at 24 h post-treatment of TNF- α . Scale bar: 100 μ m.

Supplementary Figure S3



Supplementary Figure S3. The effect of one-time SP treatment on ADSC-Y cellular viability and Akt/Erk signaling.

(A) Experimental scheme for SP and TNF- α treatment. (B) After treating ADSC with SP and TNF- α , cell viability was evaluated by WST-1 assay. (C-E) p-Akt/t-Akt and p-Erk/t-Erk protein levels were detected by Western blot analysis, and their expression level was quantified using the Image J program. p values of less than 0.05 were considered statistically significant (***) $p < 0.001$). The data are expressed as the mean \pm standard deviation (SD) of three independent experiments.